Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for Gossamer Bio (GOSS) over the last 4 years, with Sep 2025 value amounting to $1.9 million.

  • Gossamer Bio's Cash from Financing Activities rose 566.19% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 119.12%. This contributed to the annual value of -$11.5 million for FY2024, which is 106.04% down from last year.
  • Latest data reveals that Gossamer Bio reported Cash from Financing Activities of $1.9 million as of Q3 2025, which was up 1,891.49% from $94,000 recorded in Q2 2025.
  • Gossamer Bio's 5-year Cash from Financing Activities high stood at $198.5 million for Q3 2023, and its period low was -$9.2 million during Q2 2024.
  • In the last 3 years, Gossamer Bio's Cash from Financing Activities had a median value of -$1.2 million in 2023 and averaged $18.1 million.
  • As far as peak fluctuations go, Gossamer Bio's Cash from Financing Activities tumbled by 13,928.57% in 2023, and later soared by 566.19% in 2025.
  • Over the past 4 years, Gossamer Bio's Cash from Financing Activities (Quarterly) stood at -$2.9 million in 2022, then decreased by 1.04% to -$2.9 million in 2023, then tumbled by 99.86% to $281,000 in 2024, then soared by 566.19% to $1.9 million in 2025.
  • Its Cash from Financing Activities was $1.9 million in Q3 2025, compared to $94,000 in Q2 2025 and $504,000 in Q1 2025.